Regeneron Pharmaceuticals, Inc. (REGN)

883,20 -7,48 (-0,84%) Alla chiusura: 04:00PM EDT

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 13.450

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Leonard S. Schleifer M.D., Ph.D.	Co-Founder, President, CEO & Co-Chairman	8,18M	N/D	1953
Dr. George D. Yancopoulos M.D., Ph.D.	Co-Founder, President, Chief Scientific Officer & Co-Chairman	7,76M	N/D	1960
Dr. Andrew J. Murphy Ph.D.	Executive Vice President of Research	1,68M	21,37M	1959
Dr. John Lin	Senior VP of Immuno-Oncology & Head of Bispecifics	N/D	N/D	N/D
Dr. Hanne Bak	Senior Vice President of Preclinical Manufacturing & Process Development	N/D	N/D	N/D
Dr. Aris Baras M.D.	Senior Vice President of Regeneron Genetics Center	N/D	N/D	N/D
Dr. Brian P. Zambrowicz Ph.D.	Executive VP of Functional Genomics & Chief VelociGene Operations	N/D	N/D	1963
Dr. Israel Lowy M.D., Ph.D.	Senior Vice President of Translational & Clinical Sciences - Oncology	N/D	N/D	N/D
Mr. Justin Holko	Senior Vice President of Global Oncology & Hematology Commercial Business Unit	N/D	N/D	N/D
Mr. Nouhad Husseini	Senior VP of Business Development & MD	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Governance aziendale

L'ISS Governance QualityScore di Regeneron Pharmaceuticals, Inc. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 10; diritti degli azionisti: 10; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.